The poster titled “Preclinical and Translational Pharmacokinetics ... the risks that actual results of the Company’s restructuring plan and revised business plan will not be as expected; risks ...

The first presentation will spotlight JR-479, an investigational BBB-penetrating β-Hexosaminidase A (rDNA origin) enzyme replacement therapy (ERT) that JCR is developing for the treatment of people ...

But the future of one of the most quintessential neighborhood business districts in the Boston ... denying responsibility for it, as the poster had invited people to attend its meetings.

In a rare occurrence, rights group Greenpeace on Tuesday put up a poster inside the main venue of the World ... (Only the headline and picture of this report may have been reworked by the Business ...